These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 7629429)

  • 1. Eosinophilia induced by interleukin-2 cancer immunotherapy may be associated with enhanced production of total IgE.
    Vecchi L; Lissoni P
    Int J Biol Markers; 1995; 10(1):59-60. PubMed ID: 7629429
    [No Abstract]   [Full Text] [Related]  

  • 2. Renal cell cancer: is immunotherapy dead?
    Wagstaff J
    Ann Oncol; 2007 Jul; 18 Suppl 9():ix94-7. PubMed ID: 17631604
    [No Abstract]   [Full Text] [Related]  

  • 3. Reduction of brain metastasis following immunotherapy with interleukin-2 for stage IV renal cell cancer.
    Citterio G; Di Lucca G; Scaglietti U; Gilberti S; Baldini M; Rugarli C
    Acta Oncol; 1997; 36(2):228. PubMed ID: 9140444
    [No Abstract]   [Full Text] [Related]  

  • 4. Immunotherapy for renal cell carcinoma.
    Rosenblatt J; McDermott DF
    Hematol Oncol Clin North Am; 2011 Aug; 25(4):793-812. PubMed ID: 21763968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting response to interleukin-2 therapy among patients with renal cell carcinoma.
    Leppert JT; Lam JS; Belldegrun AS
    J Immunother; 2005; 28(5):427-9. PubMed ID: 16113598
    [No Abstract]   [Full Text] [Related]  

  • 6. Metastatic renal cell carcinoma: systemic treatment.
    Abi-Aad AS; deKernion JB
    Acta Urol Belg; 1996 May; 64(2):3-8. PubMed ID: 8701805
    [No Abstract]   [Full Text] [Related]  

  • 7. Intratumoural and peripheral blood lymphocyte subsets in patients with metastatic renal cell carcinoma undergoing interleukin-2 based immunotherapy: association to objective response and survival.
    Donskov F; Bennedsgaard KM; Von Der Maase H; Marcussen N; Fisker R; Jensen JJ; Naredi P; Hokland M
    Br J Cancer; 2002 Jul; 87(2):194-201. PubMed ID: 12107842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-tumor effects of interleukin 2 against renal cell carcinoma. In vitro study and clinical application.
    Marumo K; Tazaki H
    Prog Clin Biol Res; 1990; 350():263-73. PubMed ID: 2117286
    [No Abstract]   [Full Text] [Related]  

  • 9. Immunotherapy for metastatic renal cell carcinoma.
    McDermott DF; Rini BI
    BJU Int; 2007 May; 99(5 Pt B):1282-8. PubMed ID: 17441925
    [No Abstract]   [Full Text] [Related]  

  • 10. A Phase I/Ib study of folate immune (EC90 vaccine administered with GPI-0100 adjuvant followed by EC17) with interferon-α and interleukin-2 in patients with renal cell carcinoma.
    Amato RJ; Shetty A; Lu Y; Ellis PR; Mohlere V; Carnahan N; Low PS
    J Immunother; 2014 May; 37(4):237-44. PubMed ID: 24714357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of advanced renal cancer.
    Atkins MB
    Kidney Int; 2005 May; 67(5):2069-82. PubMed ID: 15840065
    [No Abstract]   [Full Text] [Related]  

  • 12. Studies of the immunological effects of interleukin-2 in patients with bladder cancer and renal cell carcinoma.
    Hermann GG
    APMIS Suppl; 1993; 35():1-26. PubMed ID: 8251200
    [No Abstract]   [Full Text] [Related]  

  • 13. Renal cancer immunotherapy: a ray of hope or regression to the mean?
    Stadler W
    Cancer Invest; 2000; 18(5):490-1. PubMed ID: 10834033
    [No Abstract]   [Full Text] [Related]  

  • 14. Integrative tumor board: metastatic renal cell carcinoma: medical oncology (II).
    Pandha H
    Integr Cancer Ther; 2004 Mar; 3(1):29-34. PubMed ID: 15035872
    [No Abstract]   [Full Text] [Related]  

  • 15. Immunotherapeutic approaches for renal cancer.
    Pizza G; de Vinci C; Viza D
    Folia Biol (Praha); 2002; 48(5):167-81. PubMed ID: 12448765
    [No Abstract]   [Full Text] [Related]  

  • 16. Immunotherapy for renal carcinoma: theoretical basis and current standard of care.
    Vasey PA
    Br J Clin Pharmacol; 2000 Dec; 50(6):521-9. PubMed ID: 11136291
    [No Abstract]   [Full Text] [Related]  

  • 17. Ten-year survival results in metastatic renal cell cancer patients treated with monoimmunotherapy with subcutaneous low-dose interleukin-2.
    Lissoni P; Bordin V; Vaghi M; Fumagalli L; Bordoni A; Mengo S; Bucovec R; Fumagalli E; Malugani F; Ardizzoia A; Giani L; Gardani GS; Tancini G
    Anticancer Res; 2002; 22(2B):1061-4. PubMed ID: 12168901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of interleukin-2 alone in disseminated renal cell carcinoma: an update.
    Javadpour N; Lalehzarian M
    Prog Clin Biol Res; 1989; 303():671-9. PubMed ID: 2789391
    [No Abstract]   [Full Text] [Related]  

  • 19. Biologic response modifiers in the therapy of metastatic renal cell carcinoma.
    Quesada JR
    Semin Oncol; 1988 Aug; 15(4):396-407. PubMed ID: 2457256
    [No Abstract]   [Full Text] [Related]  

  • 20. New views on rejection mechanisms and their relevance to interleukin-2 as a treatment for renal cell cancer.
    Oliver RT
    Eur J Cancer; 1991; 27(9):1168-72. PubMed ID: 1835631
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.